Ymmunobio AG

RIEHEN, Switzerland, April 18, 2025 /PRNewswire/ -- Ymmunobio AG (YB), a Swiss-based global biotech company dedicated to the development of new cancer therapeutics, is proud to announce that its two-antibody drug conjugate (ADC) assets, YB-800ADC1 and YB-800ADC2, have completed the preclinical proof of concept studies. Both in vivo and in vitro studies have reached this important milestone by demonstrating the anti-tumor efficacy of both ADCs. Continue Reading Ymmunobio AG The ADCs are derived from YB's lead antibody YB-800 which targets a novel and first in class tumor marker. They utilize established payloads and a third-generation linker, demonstrating a tumor growth inhibition of 90%. "These excellent results allow YB to move forward swiftly to prepare for the pivotal toxicology studies. This is a major step towards the clinical development of our ADCs in solid tumors and demonstrates the potential for YB's ADCs to address unmet needs for cancer patients expressing the new novel tumor marker. In addition, the proof-of-concept data support the preclinical development of the two YB-800 based radiopharmaceuticals developed in collaboration with the Paul Scherer Institute," said Peter Schiemann, CEO. About Ymmunobio Ymmunobio is at the forefront of oncology research, focusing on a novel target receptor for the treatment of solid tumors with high unmet need. Currently, in pre-clinical development, Ymmunobio's research is dedicated to advancing three treatment options solid tumors, with their innovative Theranostic platform: 1. YB-800ADCs, 2. YB-800R (radiopharmaceutical; therapeutic & diagnostic) in collaboration with the Paul-Scherrer-Institute and 3. YB-800BiTEs featuring aCD3 For more information about supporting Ymmunobio's initiatives, contact YB CEO Peter Schiemann at [email protected] or YBs communications team at [email protected], +41 (0) 76 378 59 30. SOURCE Ymmunobio AG WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

PRINCETON, NJ, USA I January 23, 2025 I Ymmunobio (YB) is excited to share that they in collaboration with the Paul Scherrer Institute (PSI) have received Innosuisse support to develop innovative radioactive loaded antibodies for the treatment and diagnostic of solid tumors based on YBs proprietary YB-800. The Innosuisse support validates Ymmunobio’s approach to targeted solid tumor therapy using a new and first in class target with a high prevalence in cancer patients. The newly developed antibodies will utilize a linker attached to YB-800, capable of carrying any radioactive isotope for the treatment and diagnostic of solid tumors. Ymmunobio plans to leverage this cutting-edge technology to treat patients with solid tumors who express the new marker. Radiolabeled antibodies will enhance physicians’ ability to diagnose using SPECT imaging while simultaneously targeting solid tumors that evade current therapies, paving the way for more personalized and effective treatment strategies. Dr. Peter Schiemann, Ymmunobio CEO and Chair of the Board says: “The support by Innosuisse validates our novel and first in class approach to solid tumor treatment and improving patient outcomes through advanced diagnostic and therapeutic solutions. We are proud to have received this Innosuisse validation and to have found an exceptional partner to co-develop these new treatment options for patients. Together, YB and PSI are pioneering advances in diagnostics and treatments in oncology, working towards a future where healthcare is more personalized, precise, and effective for all patients.” Dr. Martin Behe, project leader at PSI, is excited about project: “Radiolabeled compounds for cancer therapy and diagnosis have attracted significant attention from both physicians and the industry. Several of these radiopharmaceuticals have been successfully tested in clinical trials and are now routinely used in therapies, such as for prostate cancer. We are excited to collaborate with Ymmunobio in developing a radiolabeled antibody to further improve cancer treatment. This project is made possible with the support of Innosuisse.” Ymmunobio is at the forefront of oncology research, focusing on a novel target receptor for the treatment of solid tumors with high unmet need. Currently, in pre-clinical development, Ymmunobio’s research is dedicated to advancing three treatment options for GI cancers, with their innovative platform: SOURCE: Ymmunobio

PRINCETON, N.J., Jan. 23, 2025 /PRNewswire/ -- Ymmunobio (YB) is excited to share that they in collaboration with the Paul Scherrer Institute (PSI) have received Innosuisse support to develop innovative radioactive loaded antibodies for the treatment and diagnostic of solid tumors based on YBs proprietary YB-800. The Innosuisse support validates Ymmunobio's approach to targeted solid tumor therapy using a new and first in class target with a high prevalence in cancer patients. Continue Reading Ymmunobio: Cancer Therapies for Tomorrow & Beyond The newly developed antibodies will utilize a linker attached to YB-800, capable of carrying any radioactive isotope for the treatment and diagnostic of solid tumors. Ymmunobio plans to leverage this cutting-edge technology to treat patients with solid tumors who express the new marker. Radiolabeled antibodies will enhance physicians' ability to diagnose using SPECT imaging while simultaneously targeting solid tumors that evade current therapies, paving the way for more personalized and effective treatment strategies. Dr. Peter Schiemann, Ymmunobio CEO and Chair of the Board says: "The support by Innosuisse validates our novel and first in class approach to solid tumor treatment and improving patient outcomes through advanced diagnostic and therapeutic solutions. We are proud to have received this Innosuisse validation and to have found an exceptional partner to co-develop these new treatment options for patients. Together, YB and PSI are pioneering advances in diagnostics and treatments in oncology, working towards a future where healthcare is more personalized, precise, and effective for all patients." Dr. Martin Behe, project leader at PSI, is excited about project: "Radiolabeled compounds for cancer therapy and diagnosis have attracted significant attention from both physicians and the industry. Several of these radiopharmaceuticals have been successfully tested in clinical trials and are now routinely used in therapies, such as for prostate cancer. We are excited to collaborate with Ymmunobio in developing a radiolabeled antibody to further improve cancer treatment. This project is made possible with the support of Innosuisse." Ymmunobio is at the forefront of oncology research, focusing on a novel target receptor for the treatment of solid tumors with high unmet need. Currently, in pre-clinical development, Ymmunobio's research is dedicated to advancing three treatment options for GI cancers, with their innovative platform: YB-800ADC carrying up to 8 payloads with a linker of the 3rd generation YB-800R1 (therapeutic) and YB-800R2 (diagnostic) antibodies carrying radioactive isotopes in collaboration with PSI YB-800BS, bi-specific antibodies with an aCD3 T-Cell engager. Media Contact: Selena Blackmore [email protected] +41 (0) 76 378 59 30 SOURCE Ymmunobio WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED